Evidence map›Paper›PMID 40880759›Full record

ArticleFrontiers in medicine2025

The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma.

Xiaoling Zhou, Erdan Luo, Wei Chen, Yi Deng, Bo Wu, Xia Jiang, Kaili Zhang, Fan Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoling ZhouDepartment of Pharmacy, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Erdan LuoDepartment of Good Clinical Practice, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Wei ChenDepartment of Traditional Chinese Medicine, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yi DengDepartment of Pharmacy, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Bo WuDepartment of Pharmacy, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xia JiangDepartment of Obstetrics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Kaili ZhangGraduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan.
Fan LaiDepartment of Obstetrics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bispecific antibodies (BsAbs) are widely used for the treatment of multiple myeloma (MM), but their long-term safety still provokes concerns. Methods: Adverse event (AE) data on teclistamab, talquetamab, and elranatamab between 1 August 2022 and 30 September 2024 were retrieved from the Food and Drug Administration's AE Reporting System (FAERS) database by use of Open Vigil 2.1. AEs were categorized by preferred terms (PTs) and system organ classes (SOCs) as defined by MedDRA. As widely used statistical measures in pharmacovigilance, proportional reporting (PRR) and reporting odds ratios (ROR) were employed to identify potential safety signals. Results: In total 2,789,182 reports on AEs were retrieved, including 811 for teclistamab, 446 for talquetamab and 302 for elranatamab. Significant associations with immune system disorders, nervous system disorders, benign, malignant and unspecified (incl cysts and polyps) neoplasms, and hepatobiliary disorders were found for all three BsAbs. Common PTs included cytokine release syndrome (CRS), neurotoxicity, immune effector cell-associated neurotoxicity syn-drome (ICANS), pyrexia, and neutropenia. Meanwhile, signal values varied among the three BsAbs. Notably, new safety signals numbered 14, 4, and 5 were identified for teclistamab, talquetamab, and elranatamab, respectively. Conclusion: Adverse event signals were demonstrated to vary among the three BsAbs used in MM. Significant safety signals identified in the FAERS database which were consistent with previously reported clinical trial data. Furthermore, each BsAb exhibited several novel signals. These findings provide decision-makers and healthcare providers with valuable insights into clinical practice.

Indexed as

AEsbispecific antibodiesFAERSMMpharmacovigilance

Identifiers

PMID40880759
PMCPMC12380792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.